Description
SNAP-25
Product Number 104955
The Simoa® SNAP-25 Advantage V2 Assay provides ultra-sensitive quantification of the key synaptic protein – Synaptosomal-associated protein 25 (SNAP-25).
SNAP-25 is a major component of the SNARE complex that plays a key role in the release of neurotransmitters and synaptic transmission, regulating both pre- and post-synaptic activities. Research has suggested the potential of SNAP-25 as a biomarker in neurodegenerative diseases and brain injury:
- Alzheimer’s Disease (AD): SNAP-25 levels in cerebrospinal fluid (CSF) correlate with total Tau and phosphorylated Tau, suggesting its potential to detect early synaptic loss associated with cognitive decline.
- Traumatic Brain Injury (TBI): CSF SNAP-25 level increases post-injury and may help predict long-term recovery outcomes.
With picogram sensitivity and a fully automated workflow on the HD-X system, the Simoa® SNAP-25 Advantage V2 Assay enables sensitive and scalable measurement of this critical synaptic biomarker.
Applications and Intended Use
Simoa® SNAP-25 Advantage V2 is a digital immunoassay intended for the quantitative determination of SNAP-25 concentrations in human CSF samples.
For Research Use Only.
Assay Specifications
- Compatible instruments: HD-X
- Analytical Lower Limit of Quantification (LLOQ): 2.56 pg/mL
- Lower Limit of Detection (LOD): 1.47 pg/mL
- Dynamic range: 0-1000 pg/mL
*SNAP-25 assay is also available in Simoa® Advantage version that is compatible with HD-X and SR-X. Please refer to the respective datasheet for detailed specifications.
Related Resources
- Going Beyond Cerebrospinal Fluid (CSF) Biomarkers for Alzheimer’s Disease | Quanterix
- Dynamics of synaptic damage in severe traumatic brain injury revealed by cerebrospinal fluid SNAP-25 and VILIP-1 | Quanterix
- Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease | Quanterix
Reviews
There are no reviews yet.